Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

N-Nitroso Rivaroxaban EP Impurity B

● Under Development

Katalog-Nr.::	VE0027972
CAS-Nr.::	N/A
Summenformel::	C16H18N4O6
Molare Masse::	362.34 g/mol

Wie können wir helfen?

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu

Parent drug

Rivaroxaban

IUPAC-Name

(R)-N-nitroso-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)acetamide

Pharmacopeial Synonyms

N/A

Synonyme

N/A

SMILES

O=C1N(C2=CC=C(N3C(O[C@@]([H])(CN(N=O)C(C)=O)C3)=O)C=C2)CCOC1

InChI

InChI=1S/C16H18N4O6/c1-11(21)20(17-24)9-14-8-19(16(23)26-14)13-4-2-12(3-5-13)18-6-7-25-10-15(18)22/h2-5,14H,6-10H2,1H3/t14-/m1/s1

Beschreibung

N-Nitroso Rivaroxaban EP Impurity B is an N-nitroso-class degradation product identified during synthesis and stability studies of rivaroxaban active substance. This polar, low-level impurity exhibits typical nitrosamine reactivity and requires trace-level detection due to potential genotoxicity concerns. Analytical characterization employs sensitive LC-MS/MS, GC-MS after derivatization, and high resolution MS for confirmatory identification and quantification. Control strategies include nitrosation risk assessment, optimized quench steps, reagent selection, and validated cleaning procedures to minimize formation. Stability profiling under forced degradation and storage conditions informs specification setting and routine batch release testing to ensure consistent impurity control.